BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1727915)

  • 1. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
    Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
    J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
    Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
    Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy.
    Flores JF; Rude RK; Chapman RA; Belani CP; Chang AY; Pritchard JD; Hoff JV
    Cancer; 1994 May; 73(10):2527-34. PubMed ID: 8174049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia.
    Warrell RP; Murphy WK; Schulman P; O'Dwyer PJ; Heller G
    J Clin Oncol; 1991 Aug; 9(8):1467-75. PubMed ID: 1906532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group.
    Singer FR; Ritch PS; Lad TE; Ringenberg QS; Schiller JH; Recker RR; Ryzen E
    Arch Intern Med; 1991 Mar; 151(3):471-6. PubMed ID: 1900410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of available medical therapy for hypercalcemia of malignancy.
    Mundy GR; Wilkinson R; Heath DA
    Am J Med; 1983 Mar; 74(3):421-32. PubMed ID: 6219578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
    Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
    Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study.
    Flores JF; Singer FR; Rude RK
    Miner Electrolyte Metab; 1991; 17(6):390-5. PubMed ID: 1823390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of hypercalcemia of tumoral origin with two diphosphonates].
    Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
    Schweiz Med Wochenschr; 1980 Nov; 110(48):1822-4. PubMed ID: 6792698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients.
    Ringenberg QS; Ritch PS
    Clin Ther; 1987; 9(3):318-25. PubMed ID: 3111705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
    Ostenstad B; Andersen OK
    Acta Oncol; 1992; 31(8):861-4. PubMed ID: 1290634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous etidronate in the management of malignant hypercalcemia.
    Ryzen E; Martodam RR; Troxell M; Benson A; Paterson A; Shepard K; Hicks R
    Arch Intern Med; 1985 Mar; 145(3):449-52. PubMed ID: 3919667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral diphosphonates for treating malignant hypercalcemia.
    Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
    Cancer; 1981 Oct; 48(8):1922-5. PubMed ID: 6456809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study.
    Hasling C; Charles P; Mosekilde L
    Eur J Clin Invest; 1986 Oct; 16(5):433-7. PubMed ID: 3100312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S; Tisell LE; Lindstedt G; Lundberg PA
    Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of pamidronate in patients with renal failure and hypercalcemia.
    Machado CE; Flombaum CD
    Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diphosphonates in the treatment of hypercalcemia].
    Delmas PD; Meunier PJ
    Rev Med Interne; 1984 Nov; 5(4):363-6. PubMed ID: 6240753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.